Brief: Immuneering Reports Positive Overall Survival Data For Atebimetinib (Imm-1-104) From Phase 2A Trial In Pancreatic Cancer Patients
17/06/2025 11:32
June 17 (Reuters) - Immuneering Corp IMRX.O: IMMUNEERING REPORTS POSITIVE OVERALL SURVIVAL DATA FOR ATEBIMETINIB (IMM-1-104) FROM ONGOING PHASE 2A TRIAL IN FIRST-LINE PANCREATIC CANCER PATIENTS IMMUNEERING CORP - 94% OS AND 72% PFS AT 6 MONTHS FOR ATEBIMETINIB COMBO IMMUNEERING CORP - FAVORABLE TOLERABILITY PROFILE OBSERVED FOR ATEBIMETINIB COMBO IMMUNEERING CORP - PIVOTAL TRIAL OF ATEBIMETINIB COMBO IN PANCREATIC CANCER PLANNED FOR 2026 IMMUNEERING CORP - ADDITIONAL ATEBIMETINIB CLINICAL TRIAL COMBINATION ARMS TO INITIATE IN 2026 Source text: ID:nGNX2pgmSK Further company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences